Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC study of niraparib in advanced BRCA1-like HER2-negative breast cancer
NL-OMON47829Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival rate at 4 months. Started May 2018; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47829.